Is Hikal overvalued or undervalued?

As of 8 August 2025, Hikal's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered overvalued, primarily due to its high PE ratio of 56.43, which significantly exceeds the industry average. Additionally, its EV to EBITDA stands at 14.62, while the PEG ratio is at 0.00, suggesting that growth expectations may not justify the current price levels. In comparison to its peers, Hikal's valuation metrics are notably higher; for instance, Sun Pharma has a PE of 33.19 and an EV to EBITDA of 22.43, while Cipla presents a more attractive profile with a PE of 22.23 and an EV to EBITDA of 15.61. Furthermore, Hikal's recent stock performance has been underwhelming, with a year-to-date return of -25.58%, contrasting sharply with the Sensex's positive return of 2.20% over the same period. This combination of high valuation ratios and poor stock performance reinforces the conclusion that Hikal is currently overvalued.